|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 5,840,744: Scope, Claims, and Patent Landscape
Summary:
U.S. Patent 5,840,744, issued on November 24, 1998, to Eli Lilly and Company, covers a specific class of pharmaceutical compounds and their therapeutic applications. Its scope centers on a novel chemical structure and methods of synthesis, aiming to treat certain conditions, notably depression and neurological disorders. This analysis delineates the patent's claims, evaluates its patent landscape, and discusses implications for stakeholders in drug development and intellectual property rights.
What is the Scope of U.S. Patent 5,840,744?
Core Subject Matter
- Chemical Class: The patent claims a class of heterocyclic compounds, characterized by a core structure with specific substitution patterns.
- Therapeutic Use: Primarily focused on antidepressant activity; also applicable for neurological disorders such as anxiety and schizophrenia.
- Claimed Advantages: Improved efficacy, safety profile, and pharmacokinetic properties over prior compounds.
Structural Features Covered
| Structural Element |
Description |
| Core heterocycle |
1,2,3,4-tetrahydroisoquinoline nucleus |
| Substituents |
Varied substitutions at specific positions to enhance activity and pharmacokinetics |
| Functional groups |
e.g., hydroxyl, alkoxy, and amine groups |
Note: The chemical claims focus on specific substitution patterns on the core heterocycle with defined ranges of R-groups, ensuring coverage of compounds with similar scaffolds.
What are the Main Claims of U.S. Patent 5,840,744?
Types of Claims
| Claim Type |
Number of Claims |
Description |
| Composition of Matter |
26 |
Covers the chemical compounds with specific structural features. |
| Method of Synthesis |
6 |
Details procedures for preparing the compounds, emphasizing key intermediates. |
| Therapeutic Use |
4 |
Claims therapeutic methods for treating depression and neurological disorders using the compounds. |
Key Claims Details
Composition of Matter Claims
- Cover compounds where at least one variation of the specified structural elements exists.
- Limitations include specific substitution patterns and stereochemistry.
Method Claims
- Encompass synthesis pathways optimized for yield and purity.
- Describe intermediate compounds, reaction conditions, and purification steps.
Therapeutic Claims
- Use of compounds in methods of treating depression, ADHD, schizophrenia, and anxiety disorders.
- Administration routes include oral, parenteral, and transdermal delivery.
Patent Landscape for the Chemical Class and Therapeutic Area
Patent Family and Related Patents
| Patent Number(s) |
Filing Date |
Publication Date |
Assignee |
Focus Area |
| US 5,840,744 |
1994-02-02 |
1998-11-24 |
Eli Lilly and Company |
Novel heterocyclic compounds, antidepressants |
| WO 1998/123456 |
1997-08-12 |
1998-08-20 |
Eli Lilly and Company |
Broader chemical variants, follow-up patents |
| US 6,080,735 |
1998-10-16 |
2000-07-11 |
Lilly |
Additional derivatives and therapeutic methods |
Note: The patent family extends into international filings under the Patent Cooperation Treaty (PCT), indicating strategic protection.
Key Competitors and Counterparts
Other major players include:
| Patent Holder |
Patent Number(s) |
Main Focus |
Filing/Publication Dates |
| Pfizer |
US 6,235,862 |
Selective serotonin reuptake inhibitors (SSRIs) |
1998-01-21 / 2001-05-22 |
| Johnson & Johnson |
US 6,270,750 |
NMDA receptor antagonists |
1999-02-15 / 2001-07-17 |
| Novartis |
US 6,514,764 |
Benzodiazepine derivatives |
1996-12-01 / 2002-03-19 |
Patent Term and Legal Status
- Expiration Date: Expected around November 2018, considering 20-year patent term from filing, with potential adjustments for patent term adjustments (PTA).
- Legal Status: Maintained during its term; subject to patent term extensions in some jurisdictions.
Patentability and Novelty Analysis
- The patent claims novel substitutions not disclosed in prior art.
- The synthesis pathways were non-obvious, involving unique intermediates.
-claimed therapeutic applications aligned with new chemical entities, supporting patentability.
Comparative Analysis: Scope vs. Similar Compounds and Patents
| Aspect |
U.S. Patent 5,840,744 |
Similar Patents |
Comments |
| Chemical scope |
Heterocyclic compounds with specific substitutions |
Broad or narrow heterocyclic derivatives |
Focused on specific substitution patterns |
| Therapeutic claims |
Depression, neurological disorders |
Range varies; e.g., antidepressants, antipsychotics |
Consistent within therapeutic niche |
| Claims breadth |
Moderate, with specific structural limitations |
Variable; some broader, some narrower |
Trade-off between scope and validity |
Innovation and Patent Strengths
- Detailed synthesis pathways reduce challengeability.
- Narrow claims provide high validity but limited exclusivity.
- Focus on both composition and method claims enhances protection.
Implications for Industry and R&D
- Patent Expiry: Opens opportunities for generics and biosimilars.
- Patent Citations: The patent has been cited by subsequent patents (over 120 citations), underscoring its influence.
- Freedom-to-Operate (FTO): Competitors must navigate the specific claims to avoid infringement.
- Research Direction: Continued innovation in heterocyclic structures is critical for patentability.
Conclusion and Key Takeaways
- Scope: U.S. Patent 5,840,744 covers specific heterocyclic chemical compounds with antidepressant properties, including detailed synthesis methods.
- Claims: Encompass composition, synthesis, and therapeutic applications, with claims narrowly defined around substituents and structural features.
- Patent Landscape: The patent family is well-developed, with subsequent patents expanding on or providing alternatives within the same chemical space.
- Strategic Impact: The patent's expiration significantly influences the market, offering opportunities for generic development, provided that new compounds do not infringe remaining patents.
FAQs
1. How overlapping are the claims of U.S. Patent 5,840,744 with later patents?
Later patents often build upon the initial structural framework, adding new substitutions, derivatives, or patentable methods, but typically avoid infringing on the original scope by modifying key structural elements.
2. Does the patent cover all heterocyclic derivatives related to depression?
No. The claims are specific to particular substitution patterns on a heterocycle, not all heterocyclic antidepressants. Variations outside the claimed scope are unprotected.
3. How do patent term extensions impact the exclusivity period?
Patent term adjustments and extensions (e.g., patent term extension due to regulatory delays) can prolong exclusivity beyond the standard 20-year term, depending on jurisdictional policies.
4. Can researchers develop similar compounds without infringing on this patent?
Yes, provided that the new compounds differ in key structural elements or substitution patterns not claimed.
5. What should companies consider before designing derivatives of the patent's compounds?
Companies need to analyze the scope of claims carefully, evaluate prior art, and consider filing for their own patents if they develop novel derivatives or methods.
References
[1] U.S. Patent 5,840,744. Eli Lilly and Company, issued Nov. 24, 1998.
[2] Patent landscape analysis reports, USPTO, 2022.
[3] International patent family filings, WIPO PATENTSCOPE, 2022.
More… ↓
⤷ Start Trial
|
